Pinnacle Biologics Announces the Appointment of Healthcare Executives Robert S. Altman as Chief Commercial Officer and Sharon Ayd as Chief Scientific Officer
BANNOCKBURN, Ill., June 4, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc. announced that the Board of Directors has elected Robert S. Altman, Ph.D. as Chief Commercial Officer, effective today.
Mr. Altman is a proven leader with over 20 years experience in pharmaceutical industry. He was most recently CEO and President of Marathon Pharmaceuticals, LLC. From 2004 to 2007 Bob served as Senior Vice President Marketing and Sales of Astellas Pharma US. Previously Mr. Altman worked at Abbott Laboratories for sixteen years in a variety of positions rising to VP General Manager.
Mr. Altman received his BS in Chemistry from the University of California, Riverside, his Ph.D. in Physical Chemistry from Harvard University, and his MBA from the University of Chicago, Booth School of Business.
The Board of Directors of Pinnacle Biologics Inc. also elected Sharon Ayd, Ph.D. as Chief Scientific Officer, effective today.
Sharon has recently been consulting with Pinnacle leading the Regulatory, Quality and Scientific Affairs team. She has a breadth of pharmaceutical experience in entrepreneurial minded organizations. Most recently Sharon was VP, Global R&D operations for the One 2 One business unit at Hospira Inc. Previously she held a number of operating and senior management positions at start-up biopharmaceutical companies.
Sharon received her BS in Chemistry and Biology at Northeastern Illinois University, her MBA at Lewis University and her Ph.D. in Biopharmaceutical Sciences at University of Illinois, Chicago.
"We are delighted to have Bob and Sharon join our team at Pinnacle Biologics", said Guillermo Herrera, Executive Chairman and CEO of Pinnacle. "Bob is a proven individual who brings excellent experience at driving commercial performance. Sharon brings proven experience and discipline in delivering value in organizations progressing in clinical trials and expanding indications. "
"I am thrilled to be working with this talented and committed team. Pinnacle has a distinctive portfolio of assets with great expansion potential. I am energized to be able to help with Pinnacle's continued success", said Robert Altman.
"I am happy to join with the Pinnacle team and excited to use my experience in both small biotech and large established pharmaceutical companies to fully develop all possible indications of Pinnacle's lead drug", said Sharon Ayd.
ABOUT PINNACLE BIOLOGICS:
Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.
FORWARD LOOKING STATEMENT
Except for historical information contained herein, there are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved.
CONTACT:
Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695
www.pinnaclebiologics.com
www.photofrin.com
SOURCE Pinnacle Biologics, Inc.